IPI-549 is an oral, selective phosphoinositide-3-kinase gamma (PI3K-gamma) inhibitor, and the partners believe the combination will help overcome resistance to PD-1s seen in these patients.

The current PI3K 3C inhibitors in use in advanced breast cancer are alpelisib and inavolisib. Capivasertib is an AKT inhibitor, which is also used in PI3K 3C mutated breast cancer. So these are ...